Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Dorothée Sémiond"'
Autor:
Mingyuan Sun, Hongmei Jing, Xiaoyan Qu, Fei Dong, Yi Li, Zhaoyi Feng, Samira Ziti-Ljajic, Dorothee Semiond, Lingyu Li, Junyuan Qi, Lugui Qiu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract In this multi-center, Phase-1 study (NCT03733717), we characterized the pharmacokinetics (PK) of the anti-CD38 antibody isatuximab (Isa) after IV administration (primary objective), and evaluated safety, immunogenicity, and preliminary anti-
Externí odkaz:
https://doaj.org/article/0b895c9da45f42e38c4d68e5d4bc73e9
Autor:
Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Helen Crowther, Nobuhiro Tsukada, Pierre Bories, Sumit Madan, Nitya Nathwani, Kazutaka Sunami, Dorothee Semiond, Disa Yu, Paul Cordero, Sandrine Macé, Florence Suzan, Philippe Moreau
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/8ad9129ba0484886a633e43d1cd4da44
Autor:
Hoai‐Thu Thai, Kimiko Koiwai, Yoshihisa Shitara, Hirotaka Kazama, Jean‐Baptiste Fau, Dorothée Semiond, Christine Veyrat‐Follet
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1846-1858 (2023)
Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of s
Externí odkaz:
https://doaj.org/article/daa28da7c7994013bf748c2247ab7421
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 766-777 (2022)
Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clini
Externí odkaz:
https://doaj.org/article/72a8ca4364ed43ceb08268319c1c852e
Autor:
Kimiko Koiwai, Raouf El‐Cheikh, Hoai‐Thu Thai, Claire Brillac, Jean‐Baptiste Fau, Christine Veyrat‐Follet, Marie‐Laure Risse, Helgi van deVelde, Dorothée Semiond, Laurent Nguyen
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 928-940 (2021)
Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with rela
Externí odkaz:
https://doaj.org/article/af2cc48054174339a0403cbbf840ec73
Autor:
Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey Zonder, Djordje Atanackovic, Nashat Gabrail, Thomas G. Martin, Aurore Perrot, Samira Bensfia, Qilong Weng, Claire Brillac, Dorothée Semiond, Sandrine Macé, Kathryn P. Corzo, Xavier Leleu
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 5, Pp 1-5 (2021)
Externí odkaz:
https://doaj.org/article/e988d77002f64e06a56cefb6125e9b40
Autor:
Jean‐Baptiste Fau, Raouf El‐Cheikh, Claire Brillac, Kimiko Koiwai, Nathalie Mace, Frank Campana, Dorothee Semiond, Laurent Nguyen
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 11, Pp 649-658 (2020)
Isatuximab, a monoclonal antibody (mAb) of immunoglobulin G (IgG) isotype, specifically targets the cluster of differentiation 38 antigen overexpressed in malignant plasma cells. Isatuximab is used to treat multiple myeloma (MM), characterized by the
Externí odkaz:
https://doaj.org/article/0b977e74df2045d28990c4247039121a
Autor:
Marie-Christine Bissery, François Lavelle, Alain Commerçon, Jean-François Riou, Cecile Combeau, Loreley Calvet, Hervé Bouchard, Pascale Lejeune, Dorothée Sémiond, Patricia Vrignaud
Supplementary Table S5 - PDF file 68K, In vitro antiproliferative effects of cabazitaxel against cell lines resistant to standard clinical agents not expressing P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448126853723961f345979bb19b905bf
https://doi.org/10.1158/1078-0432.22451058
https://doi.org/10.1158/1078-0432.22451058
Autor:
Marie-Christine Bissery, François Lavelle, Alain Commerçon, Jean-François Riou, Cecile Combeau, Loreley Calvet, Hervé Bouchard, Pascale Lejeune, Dorothée Sémiond, Patricia Vrignaud
Purpose: Taxanes are important chemotherapeutic agents with proven efficacy in human cancers, but their use is limited by resistance development. We report here the preclinical characteristics of cabazitaxel (XRP6258), a semisynthetic taxane develope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f50971ac9988c5f0a91c3688b145351
https://doi.org/10.1158/1078-0432.c.6522087.v1
https://doi.org/10.1158/1078-0432.c.6522087.v1
Autor:
Marie-Christine Bissery, François Lavelle, Alain Commerçon, Jean-François Riou, Cecile Combeau, Loreley Calvet, Hervé Bouchard, Pascale Lejeune, Dorothée Sémiond, Patricia Vrignaud
Supplementary Fig. S1 - PDF file 60K, Taxane chemical structures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be2949c3b4a9d768d2ecb243bd2a9d0
https://doi.org/10.1158/1078-0432.22451073.v1
https://doi.org/10.1158/1078-0432.22451073.v1